Legend Biotech (LEGN) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Legend Biotech has reported preliminary net trade sales of approximately $286 million for its CARVYKTI® product in the third quarter of 2024. This announcement reflects data provided by its partner, Janssen Biotech, though it has not been independently verified by Legend Biotech. Investors may find these figures promising as they highlight the company’s growing presence in the biotech market.
For further insights into LEGN stock, check out TipRanks’ Stock Analysis page.